Peptide Knowledge Base · Recovery

BPC-157: what it is, what the evidence says, and its real status

The recovery peptide everyone's talking about, with loud buzz and thin human proof.

Can you actually get it?

Plain-English verdict: Join waitlist.

Regulatory status: PCAC recommended · rulemaking pending.

How does BPC-157 work?

A 15-amino-acid sequence derived from a protein in gastric juice; proposed to support angiogenesis and tissue repair signaling.

What it does — and what it does not do

What it does: Studied for soft-tissue and gut-lining repair support.

What it does not do: It is not a proven cure for any injury.

How honest is the evidence?

Evidence grade D — Animal and lab evidence; human trials still to come.

animal-dominant, fewer than 30 humans, no placebo-controlled efficacy trials

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Fewer than 30 humans have been studied, with no placebo-controlled efficacy trials. Long-term safety is uncharacterized.

WADA status: Banned (S0).

How it is taken

No established human clinical dosing; research-stage only.

Who should not take it

Not characterized in humans; banned in tested sport (WADA S0). Not for anyone subject to anti-doping rules.

Sources

Sikiric et al., BPC-157 cytoprotection reviews (J Physiol Pharmacol) · FDA PCAC docket, Jul 2026

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 16, 2026 · Peptós.LIFE · Not medical advice.